MARKET

RXRX

RXRX

Recursion Pharmaceuticals, Inc.
NASDAQ
3.980
+0.420
+11.80%
After Hours: 3.979 -0.001 -0.02% 19:57 02/06 EST
OPEN
3.740
PREV CLOSE
3.560
HIGH
4.020
LOW
3.690
VOLUME
26.27M
TURNOVER
--
52 WEEK HIGH
12.36
52 WEEK LOW
3.540
MARKET CAP
2.07B
P/E (TTM)
-2.1997
1D
5D
1M
3M
1Y
5Y
1D
This $4 Stock Could Be Your Ticket to Millionaire Status
The Motley Fool · 14h ago
Cathie Wood ‘Buys the Dip’ in GOOGL Stock, Trims Coinbase (COIN) after 13% Rally
TipRanks · 23h ago
Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares
Reuters · 1d ago
Recursion Pharmaceuticals Director Blake Borgeson Reports Sale of Common Shares
Reuters · 1d ago
Recursion’s REC-4881 Cancer Trial Terminated: Reading the Signals for RXRX Investors
TipRanks · 1d ago
OpenAI considers backing AI-led drug discovery firms: report
Seeking Alpha · 4d ago
Weekly Report: what happened at RXRX last week (0126-0130)?
Weekly Report · 6d ago
Private Markets: Nvidia, Microsoft consider new investment in OpenAI
TipRanks · 01/30 15:51
More
About RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.

Webull offers Recursion Pharmaceuticals Inc stock information, including NASDAQ: RXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RXRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RXRX stock methods without spending real money on the virtual paper trading platform.